Of those who were ever CKD-registered, 1829/3235 (56.5%) were registered within one year of their first low eGFR (Table 1). This represented 14.1% of the total study population with CKD (n = 12,988).

Verma and colleagues also noted that the absolute risk differences were 7.9% and 10.7%, respectively, when comparing patients with UACR levels of 15 mg/g or more to patients with UACR of 5 mg/g to ...

Early combination therapy could translate into fewer downstream hospitalizations and lower costs associated with dialysis and cardiovascular complications.

This phase 2, multicenter, randomized, double-blind trial enrolled 818 adults with CKD (eGFR 30–90 ml/min/1.73 m²) and T2D, with a UACR between 100 and <5,000 mg/g, all receiving a maximally ...

Patients were stratified on the basis of UACR levels of 0-5 mg/g, 5 to < 15 mg/g, and ≥ 15 mg/g. Over a median of a 9.8-year follow-up, 182 of the 1629 patients had progression of CKD. TAKEAWAY: ...

Mean age was 64.1, and most patients (78.1%) were white. They determined the percentage of patients who had both guideline-recommended tests—eGFR and uACR—as well as those who had just 1 of ...

Chronic kidney disease (CKD) affects millions worldwide and is a major global health issue which is characterized by the ...

Additionally, there was a notable increase in prescriptions for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (7.5% vs 4.4%; P = .024) and sodium-glucose cotransporter 2 ...

Similarly, 17.8% of those with stage G1-A2 CKD, 44% of those with stage G2-A2 and 61.3% of those with stage G3a-A1 CKD patients progressed to a higher KDIGO risk category.